Bevacizumab in the treatment of HER2-negative breast cancer
Vito LorussoOncologic Institute, Vito Fazzi Hospital, Lecce, ItalyAbstract: Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the treatment of metastatic breast cancer (MBC). Be...
Saved in:
Main Author: | Vito Lorusso |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2008
|
Subjects: | |
Online Access: | https://doaj.org/article/63902e14daea4d16883e5a78a2bcb251 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current neoadjuvant treatment options for HER2 positive breast cancer
by: Abdel-Razeq H, et al.
Published: (2011) -
Bevacizumab in the treatment of ovarian cancer
by: Ramez N Eskander, et al.
Published: (2011) -
HER2 breast cancer therapies: a review
by: Conleth G Murphy, et al.
Published: (2009) -
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
by: Jia Li, et al.
Published: (2009) -
Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer
by: Shogo Nakamoto, et al.
Published: (2021)